Почетна › Автоимуни болести › Калифорнија
Клинички испитувања за Автоимуни болести во Калифорнија
27 студии за Автоимуни болести бараат учесници на локации во Калифорнија.
Градови во Калифорнија
- Los Angeles12 студии
- San Francisco7 студии
- Orange7 студии
- Mountain View6 студии
- San Diego5 студии
- Sacramento5 студии
- Irvine3 студии
Официјален текст на студијата (англиски)
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
- City of Hope Comprehensive Cancer Center, Duarte
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06817889A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Jade Clinical Site, Chula Vista
Се регрутираФаза 2
Возраст од 18 до 60 · Сите полови · Ажурирано 25.9.2026 · NCT07541287Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of California Davis Comprehensive Cancer Center, Sacramento
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT03816345A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
- University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 18.9.2026 · NCT06722235RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- University of California Irvine - Accepting Adult Patients, Orange
- University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients, San Francisco
Се регрутираФаза 2/3
Возраст од 6 до 75 · Сите полови · Ажурирано 17.9.2026 · NCT06154252A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
- University of Southern California, Los Angeles
Се регрутираФаза 3
Возраст од 18 до 70 · Сите полови · Ажурирано 11.9.2026 · NCT07059000A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Loma Linda University Medical Center, Loma Linda
Се регрутираФаза 1
Возраст од 18 до 74 · Сите полови · Ажурирано 10.9.2026 · NCT07085104A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
- University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT06948318A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Orange
- и уште 2
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT06572384RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- University of California Irvine, Orange
- UC Davis Health, Sacramento
Се регрутираФаза 1/2
Возраст од 18 до 65 · Сите полови · Ажурирано 26.8.2026 · NCT06121297RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- University of California Irvine, Orange
- UC Davis, Department of Neurology, Sacramento
- University of California, San Francisco, San Francisco
Се регрутираФаза 1/2
Возраст од 18 до 70 · Сите полови · Ажурирано 13.8.2026 · NCT06359041A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- UC Irvine, Irvine
- Orso Health, La Jolla
- University of California, Los Angeles-UCLA, Los Angeles
Се регрутираФаза 3
Возраст 12 и постари · Сите полови · Ажурирано 6.8.2026 · NCT06056297Study of BHV-1300 in Graves' Disease
- Site-103, South Gate
Се регрутираФаза 1
Возраст од 18 до 65 · Сите полови · Ажурирано 31.7.2026 · NCT06980649Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1010, Carlsbad
- Site Number - 1028, Irvine
- Site Number - 1023, Los Angeles
- и уште 2
Се регрутираФаза 3
Возраст од 18 до 80 · Сите полови · Ажурирано 30.7.2026 · NCT07039916KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Ronald Reagan UCLA Medical Center, Los Angeles
- University of California, Irvine, Orange
- Stanford University Medical Center, Palo Alto
Се регрутираФаза 2/3
Возраст од 18 до 75 · Сите полови · Ажурирано 29.7.2026 · NCT06193889A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- City of Hope, Duarte
- Children's Hospital of Los Angeles, Glendale
- Scripps Green Hospital, La Jolla
- и уште 8
Се регрутираНабљудувачка студија
Сите возрасти · Сите полови · Ажурирано 6.7.2026 · NCT01351545Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
- UCSF Medical Center, San Francisco
- Stanford Medical Center, Stanford
Се регрутираФаза 1
Возраст од 18 до 70 · Сите полови · Ажурирано 30.6.2026 · NCT06201416Atacicept in Multiple Glomerular Diseases
- Vera Therapeutics, Brisbane
Се регрутираФаза 2
Возраст 2 и постари · Сите полови · Ажурирано 26.6.2026 · NCT06983028A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- Stanford University, Dept. of Dermatology, Redwood City
- UC Davis, Dept. of Dermatology, Sacramento
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 29.5.2026 · NCT04422912A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Wallace Rheumatic Center, Beverly Hills
- Providence Medical Foundation, Fullerton
- University of California Irvine, Irvine
- и уште 2
Се регрутираФаза 1
Возраст од 12 до 70 · Сите полови · Ажурирано 22.5.2026 · NCT06308978A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
- Stanford Multiple Sclerosis Center, Palo Alto
Се регрутираФаза 1
Возраст од 18 до 65 · Сите полови · Ажурирано 27.2.2026 · NCT06138132A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- UCLA Medical Center, Los Angeles
- University of California, Irvine, Orange
- Stanford Hospital, Palo Alto
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 25.2.2026 · NCT06626919Central Vein Sign in Multiple Sclerosis Extension Study
- Cedars-Sinai Medical Center, Los Angeles
Се регрутира
Возраст од 18 до 65 · Сите полови · Ажурирано 20.2.2026 · NCT07424027CD4^LVFOXP3 in Participants With IPEX
- Lucile Packard Children's Hospital, Palo Alto
Се регрутираФаза 1
4 Months – 35 Years · Мажи · Ажурирано 22.5.2025 · NCT05241444Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
- University of California, San Diego, La Jolla
Се регрутираНабљудувачка студија
Сите возрасти · Жени · Ажурирано 28.1.2025 · NCT02103361Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
- MiraKind, Los Angeles
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст 18 и постари · Сите полови · Ажурирано 23.1.2025 · NCT02253251Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
- Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites, Culver City
Се регрутираФаза 1/2Добредојдени се здрави волонтери
Возраст 18 и постари · Сите полови · Ажурирано 29.4.2022 · NCT04684602Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.